Tapering off Mounjaro: the facts behind a common question

The taper myth: where it comes from and why tirzepatide is different

The assumption that Mounjaro needs to be tapered is understandable. Many long-term medicines (corticosteroids, antidepressants, beta-blockers) do require a gradual wind-down to avoid rebound or withdrawal effects. Tirzepatide is not in that category. It is a dual GIP and GLP-1 receptor agonist that works by signalling through hormone pathways to reduce appetite and slow gastric emptying; it does not suppress adrenal function or alter neurotransmitter levels in a way that demands step-by-step reduction.

The Mounjaro prescribing information published on the eMC does not describe a tapering schedule before stopping. In the major clinical trials (including SURMOUNT-1, which followed thousands of adults over 72 weeks) participants moved from their maintenance dose to placebo without a step-down period. That is not a minor footnote; it reflects how the pharmacology actually works.

Where confusion arises is around the upward titration at the start of treatment. Doses do increase gradually (from 2.5 mg, with the prescriber adding steps every four weeks or so) but that escalation exists to let your digestive system adjust, not because the medicine needs building up therapeutically. The logic runs in one direction only. If you want to understand more about what tirzepatide is and how it acts in the body, the tirzepatide overview covers the mechanism in plain terms.

What actually happens when Mounjaro stops

Tirzepatide's half-life is roughly five days. That means, after your last injection, the medicine does not vanish overnight; it clears steadily over the following week or two. During that window some people notice their appetite beginning to return, often more noticeably by day five or six of a missed week. There is a separate page on the wearing-off feeling that many patients describe towards the end of each injection cycle, which gives useful context here.

Once tirzepatide has fully cleared, the appetite-suppressing and gut-slowing effects reverse. The biological drivers of weight gain (many of which are hormonal rather than behavioural) reassert themselves. Clinical trial follow-up data show meaningful weight regain in the year after stopping, which is one reason prescribers consider ongoing treatment carefully rather than treating it as a fixed course. This is not a reason to feel alarmed; it is a reason to plan. Keeping up the dietary patterns and activity habits built during treatment is genuinely protective, even if it does not fully offset the pharmacological change.

If you have concerns about what to expect in the days after an injection, the page on day five specifically addresses the timeline in more detail.

When stopping Mounjaro is the right decision, and how to approach it

There are legitimate reasons a prescriber might recommend stopping: significant side effects that persist despite dose adjustment, a planned pregnancy, a surgical procedure, or simply a shared clinical decision that treatment goals have been met. Occasionally people need to pause because of supply or cost changes; the cost context page covers what private treatment typically involves.

Whatever the reason, the process starts with a conversation. Your prescriber will consider how long you have been on treatment, your current dose, your weight trajectory and any underlying conditions before advising you. They may also want to plan follow-up, since the period after stopping is when lifestyle support matters most. NHS guidance on weight-management medicines, available on the NHS England weight management injections page, consistently emphasises that medicines work best alongside dietary and activity changes, and that stopping does not mean those changes stop too.

Practically speaking: if your pen is stored in the fridge door and you decide, in discussion with your prescriber, that your next injection date has passed without one, resist the urge to double up. A missed injection is not recovered by taking two doses close together, ask your prescriber or check the Patient Information Leaflet for guidance specific to your situation. The detailed guide on how to approach stopping Mounjaro walks through the practical steps your prescriber is likely to discuss with you.

What to do if you are considering stopping

The honest answer is: talk first. Adjusting a prescription medicine unilaterally (even by simply not ordering the next pen) is worth discussing in advance rather than after. Your prescriber can give you a realistic picture of what to expect, address any side effects that may be driving the decision, and help you plan the transition rather than navigate it alone.

At nume, every repeat order is reviewed by a named clinician before it is processed, not by a system working through a checklist, but by a real prescriber reading your notes. That same prescriber relationship is there if you have questions about pausing or stopping treatment. You can also read more on the coming off Mounjaro page, which covers the broader picture of what patients experience after ending treatment. If you would like to talk through your options, speak to our prescribers through a free consultation. The FAQs also address common questions about managing treatment.

Mounjaro is covered in detail on the NHS medicines pages, including side effects and what to do if you miss a dose, a useful reference alongside any conversation with your prescriber.